The first public molecular recognition database, BindingDB supports research, education and practice in drug discovery, pharmacology and related fields.

BindingDB contains 3.2M data for 1.4M Compounds and 11.5K Targets. Of those, 1.6M data for 765K Compounds and 4.8K Targets were curated by BindingDB curators. BindingDB is a FAIRsharing resource.

If BindingDB was of value to your research, please take a moment to donate to this nonprofit project. Your donation will let us provide you with more data and improved service.

To help with training and testing AI and other models, BindingDB downloads and search results now provide the publication date and BindingDB curation date of each measurement.

25 articles for thisTarget


The following articles (labelled with PubMed ID or TBD) are for your review

PMID
Cmpds
Data
Article Title
Organization
3
Synthesis and biological evaluation of a unique heparin mimetic hexasaccharide for structure-activity relationship studies.EBI
Momenta Pharmaceuticals
4
Improved total synthesis and biological evaluation of potent apratoxin S4 based anticancer agents with differential stability and further enhanced activity.EBI
University of Florida
4
Bioassay-guided isolation of proanthocyanidins with antiangiogenic activities.EBI
University of Salerno
25
A focused sulfated glycoconjugate Ugi library for probing heparan sulfate-binding angiogenic growth factors.EBI
The University of Queensland
17
Synthesis and biological evaluation of polysulfated oligosaccharide glycosides as inhibitors of angiogenesis and tumor growth.EBI
Progen Pharmaceuticals
13
Recent progress in the development of hypoxia-inducible factor 2α (HIF-2α) modulators: Inhibitors, agonists, and degraders (2009-2024).EBI
Hubei Polytechnic University
6
Discovery of a Dual Tubulin and Neuropilin-1 (NRP1) Inhibitor with Potent In Vivo Anti-Tumor Activity via Pharmacophore-based Docking Screening, Structure Optimization, and Biological Evaluation.EBI
China Pharmaceutical University
10
Dimer Peptide Ligands of Vascular Endothelial Growth Factor: Optimizing Linker Length for High Affinity and Antiangiogenic Activity.EBI
University Paris Cite
4
Synthesis, biological activity, and preliminary pharmacokinetic evaluation of analogues of a phosphosulfomannan angiogenesis inhibitor (PI-88).EBI
Progen Industries
4
1,4-DIHETEROCYCLIC SUBSTITUTED AROMATIC RING OR AROMATIC HETEROCYCLIC COMPOUND AND USE THEREOFBDB
Bebetter Med
18
PYRIDINO-OR PYRIMIDO-CYCLIC COMPOUND, PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOFBDB
Genfleet Therapeutics (Shanghai)
123
HSD17B13 INHIBITORS AND/OR DEGRADERSBDB
Pfizer
53
AMPK activatorsBDB
Kallyope
29
Cyanopyrrolidine derivatives as inhibitors for DUBsBDB
Mission Therapeutics
107
Spiro[3H-indole-3,2′-pyrrolidin]-2(1H)-one compounds and derivatives as MDM2-P53 inhibitorsBDB
Boehringer Ingelheim International
116
Pyrrolidine derivatives and their use as complement pathway modulatorsBDB
Novartis
8
Quaternized amines as sodium channel blockersBDB
Purdue Pharma
23
Design, synthesis and SAR study of hydroxychalcone inhibitors of human ß-secretase (BACE1).BDB
Shanghai Institute of Material Medica, Chinese Academy of Sciences
210
Pyrrolo[3,2-c]pyridine tropomyosin-related kinase inhibitorsBDB
Pfizer
818
Flap modulatorsBDB
Janssen Pharmaceutica
2
1′-substituted pyrimidine N-nucleoside analogs for antiviral treatmentBDB
Gilead Sciences
44
MAPK/ERK kinase inhibitorsBDB
Takeda Pharmaceutical